Retatrutide: The Triple Agonist That Lost 71 Pounds in Trials
Market snapshot: Retatrutide is Eli Lilly's investigational triple hormone receptor agonist — the first drug to simultaneously activate GLP-1, GIP, and glucagon receptors. In the Phase 3 TRIUMPH-4 trial, the highest dose produced an average 28.7% body weight loss (~71 lbs) over 68 weeks. Seven additional Phase 3 trials are reporting throughout 2026, with FDA submission expected by late 2026 or early 2027.
Every generation of GLP-1 medication has added a receptor. Semaglutide (Ozempic, Wegovy) targets one receptor: GLP-1. Tirzepatide (Mounjaro, Zepbound) targets two: GLP-1 and GIP. Retatrutide targets three: GLP-1, GIP, and glucagon.
The additional glucagon receptor activation drives greater energy expenditure and fat oxidation — and the clinical data reflects it. This is the most effective weight-loss compound ever tested in clinical trials.
TRIUMPH-4 Results: The Numbers
TRIUMPH-4, the first Phase 3 trial to report, studied retatrutide in adults with obesity and knee osteoarthritis. Results announced December 2025:
| Metric | Retatrutide 12mg | Placebo |
|---|---|---|
| Average weight loss | 28.7% (~71.2 lbs) | ~2% |
| Osteoarthritis pain reduction | Substantial improvement | Minimal |
| Physical function improvement | Statistically significant | — |
| Non-HDL cholesterol reduction | Clinically meaningful | — |
| Systolic blood pressure | Reduced | — |
How Retatrutide Compares to Current Medications
| Medication | Mechanism | Peak Weight Loss (Trials) | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 mono-agonist | ~15% at 68 weeks | FDA-approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP dual-agonist | ~22.5% at 72 weeks | FDA-approved |
| Orforglipron (Foundayo) | Non-peptide GLP-1 | ~12.4% at 72 weeks | FDA-approved (April 2026) |
| Retatrutide | GLP-1 + GIP + glucagon triple-agonist | ~28.7% at 68 weeks | Phase 3 (not approved) |
Retatrutide's 28.7% weight loss nearly doubles what semaglutide achieves and exceeds tirzepatide by roughly 6 percentage points. If the full Phase 3 program confirms these results and the safety profile holds, this would represent the largest pharmacological weight loss ever achieved.
The TRIUMPH Phase 3 Program
Eight Phase 3 trials are evaluating retatrutide across multiple conditions:
- TRIUMPH-4 (reported Dec 2025): Obesity + knee osteoarthritis — 28.7% weight loss
- TRANSCEND-T2D-1 (reported March 2026): Type 2 diabetes — superior A1C reduction and weight loss vs. placebo
- Additional trials reporting in 2026: Obesity/overweight, obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, renal outcomes, and MASH
Eli Lilly expects to complete the Phase 3 program by late 2026 or early 2027, which would enable an FDA submission. If the review follows typical timelines, approval could come in 2027 or 2028.
What Retatrutide Means for the Compounding Market
Retatrutide is a peptide, which means it could theoretically be compounded — but only if it enters the drug shortage list or is added to the 503B Bulks List. Given the FDA's current trajectory of explicitly excluding GLP-1s from the Bulks List, compounded retatrutide in the US market seems unlikely.
More broadly, retatrutide represents additional downward pricing pressure on the entire GLP-1 market. Each new compound gives manufacturers more incentive to compete on price, which benefits patients regardless of which specific medication they use.
Should You Wait for Retatrutide?
No. Retatrutide is at least 18–24 months from FDA approval and commercial availability. If you need treatment now, today's options — from compounded semaglutide at $99/mo to brand-name oral pills at $149/mo — are available and effective. Start now. Switch later if something better arrives.
The GLP-1 landscape will keep evolving. The right approach is to use the best available treatment today and upgrade when better options become accessible.
Compare Verified Providers
SkinnyRx
$149/mo
Three formats: injectable, sublingual, and tablets. Flexible dosing options for every preference.
Learn More Paid linkOral GLP-1 angle: sublingual + tablet options available
Compounded medications are not FDA-approved.
Embody
$149 first month / $299 refills
Injectable semaglutide. Physician-supervised with regular check-ins.
Learn More Paid linkCompounded medications are not FDA-approved.
GobyMeds
$99/mo semaglutide
Lowest price. LegitScript certified, 503A+503B. Code x7X72r saves $25.
Learn More Paid linkCompounded medications are not FDA-approved.
Gala GLP-1
$179/mo flat
No dose-tier increases at any level. Transparent pricing.
Learn More Paid linkCompounded medications are not FDA-approved.
Compare All GLP-1 Providers Side by Side
See pricing, medications, and ratings for verified telehealth providers.
View Provider Comparison →Sources
- Eli Lilly press release: TRIUMPH-4 Phase 3 results, December 11, 2025.
- Eli Lilly press release: TRANSCEND-T2D-1 results, March 19, 2026.
- Wharton et al. Phase 2 results. New England Journal of Medicine, 2023.
- GlobalData: Retatrutide sales projections, $15.6B by 2031.
- ClinicalTrialsArena: TRIUMPH program analysis.
Affiliate Disclosure: Some links on this page are paid affiliate links. If you sign up through them, we may earn a commission at no extra cost to you. This does not influence our editorial content or sourcing.
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
FDA Notice: Compounded medications referenced in this article are not FDA-approved. Only brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo) carry FDA approval for their indicated uses.